News Article | April 12, 2017
MADISON, Wis., April 12, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused clinical stage biotechnology company, today announces it has appointed John Friend, II, M.D. as vice president and chief medical officer effective April 17, 2017. “Cellectar has accelerated and expanded its research and development program to include multiple clinical trials for our lead product candidate CLR 131, as well as the active preclinical development of additional compounds utilizing our PDC platform,” said Jim Caruso, president and CEO of Cellectar Biosciences. “John’s depth of drug development experience in the biopharmaceutical industry, specifically, advancing drugs from preclinical stage through clinical studies, as well as successful oversight of the regulatory process, precisely meets our current need in helming our PDC programs and we look forward to benefitting from his leadership.” Dr. Friend, age 47, brings 15 years of global drug development expertise and general management experience in oncology, inflammation, endocrine/metabolism, and pain management to Cellectar. Prior to joining the company, John spent more than seven years at Helsinn Therapeutics leading its research and development division. Most recently he served as senior vice president of Medical and Scientific Affairs at Helsinn, building the non-clinical, clinical, medical and regulatory affairs teams to lead multiple global franchises from early product development to market commercialization. Prior to his time at Helsinn, Dr. Friend held executive responsibility for clinical research, medical affairs, pharmacovigilance and risk management at various pharmaceutical companies including Akros Pharma, Actavis, Alpharma, Hospira and Abbott. After obtaining an undergraduate degree in Chemistry from Southern Methodist University, John earned his medical degree from UMDNJ-Robert Wood Johnson Medical School (now Rutgers, RWJMS). He completed post-graduate residency program in family medicine and subsequently served as clinical director and faculty attending physician at Cabarrus Family Medicine Residency Program in North Carolina. About Cellectar Biosciences, Inc. Cellectar Biosciences is developing phospholipid drug conjugates (PDCs) designed to provide cancer-targeted delivery of diverse oncologic payloads to a broad range of cancers and cancer stem cells. Cellectar's PDC platform is based on the company's proprietary phospholipid ether analogs. These novel small-molecules have demonstrated highly selective uptake and retention in a broad range of cancers. Cellectar's PDC pipeline includes product candidates for cancer therapy and cancer diagnostic imaging. The company's lead therapeutic PDC, CLR 131, utilizes iodine-131, a cytotoxic radioisotope, as its payload. CLR 131 is currently being evaluated under an orphan drug designated Phase I clinical study in patients with relapsed or refractory multiple myeloma, as well as a Phase II clinical study to assess efficacy in a range of B-cell malignancies. The company is also developing PDCs for targeted delivery of chemotherapeutics such as paclitaxel (CLR 1603-PTX), a preclinical-stage product candidate, and plans to expand its PDC chemotherapeutic pipeline through both in-house and collaborative R&D efforts. For more information please visit www.cellectar.com. This news release contains forward-looking statements. You can identify these statements by our use of words such as "may," "expect," "believe," "anticipate," "intend," "could," "estimate," "continue," "plans," or their negatives or cognates. These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to raise additional capital, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other government regulation, our pharmaceutical collaborators' ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third-party reimbursement. A complete description of risks and uncertainties related to our business is contained in our periodic reports filed with the Securities and Exchange Commission including our Form 10-K for the year ended December 31, 2016. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update any such forward-looking statements.
News Article | June 12, 2017
The International Association of HealthCare Professionals is pleased to welcome Dr. Elissa Jeanne Santoro, MD, to their prestigious organization with her upcoming publication in The Leading Physicians of the World. She is a highly-trained Breast Surgical Oncologist with expertise in all facets of her work. Dr. Elissa Jeanne Santoro has been practicing for over 47 years and is currently on staff at the Center for Breast Health and Disease Management in Livingston, New Jersey. She is also affiliated with St. Barnabas Medical Center. Dr. Elissa Jeanne Santoro obtained her Doctor of Medicine Degree from the Women’s Medical College of Pennsylvania in 1965, where she also completed a straight surgical internship. After two years of Surgical residency at Woman’s Medical, she completed her Surgical residency at St. Vincent’s Hospital in New York City, and became the first woman to be Chief Surgical Resident. There, she received an ACS postdoctoral Fellowship in cancer training. At New York Medical College she was awarded a postdoctoral Fellowship from The National Cancer Institute, and was also on the surgical faculty. Dr. Santoro then moved to New Jersey and joined the faculty at UMDNJ. Later, she joined St. Barnabas Medical Center in Livingston, NJ private practice and in 1977 opened the first Breast Oncology practice in New Jersey. Dr. Santoro is certified by the American Board of Surgery in General Surgery, and is particularly renowned as an expert in breast surgery and surgical oncology. She remains a professional member of many professional organizations, including the American Society of Clinical Oncology, the American Society of Breast Surgeons, the American Society of Breast Disease, the Medical Society of New Jersey, and is the First Woman President of the New Jersey American Cancer Society. She attributes her success to her upbringing and her determination to become a doctor at a young age. When not assisting patients, Dr. Santoro enjoys traveling, reading, and hot air ballooning. Learn more about Dr. Santoro here: http://www.barnabashealth.org/Center-for-Breast-Health-and-Disease-Management.aspx and by reading her upcoming publication in The Leading Physicians of the World. FindaTopDoc.com is a hub for all things medicine, featuring detailed descriptions of medical professionals across all areas of expertise, and information on thousands of healthcare topics. Each month, millions of patients use FindaTopDoc to find a doctor nearby and instantly book an appointment online or create a review. FindaTopDoc.com features each doctor’s full professional biography highlighting their achievements, experience, patient reviews and areas of expertise. A leading provider of valuable health information that helps empower patient and doctor alike, FindaTopDoc enables readers to live a happier and healthier life. For more information about FindaTopDoc, visit: http://www.findatopdoc.com
News Article | June 5, 2017
JACKSONVILLE, FL--(Marketwired - June 05, 2017) - The Florida Society of Ophthalmology (FSO), the preeminent professional association for medical and osteopathic doctors who specialize in vision care, elected Krishna Kishor, M.D. as president at its annual meeting, Masters in Ophthalmology 2017, held June 2-4 in Miami, Fla. As FSO president, Kishor will help lead the nonprofit association, which represents over 500 medical doctors focused on protecting the medical and surgical specialty of ophthalmology. In addition to active participation in legislative advocacy and the dissemination of responsible information to physicians and patients throughout the state, the FSO also provides continuing medical education opportunities. Kishor is an Assistant Professor of Clinical Ophthalmology at the University of Miami/Bascom Palmer Eye Institute. In 2008, he was appointed to the Ann Bates Leach Eye Hospital and has also been at the Veterans Administration Medical Center in West Palm Beach, Fla., since 2011. Kishor received his Bachelor of Science degree from Virginia Commonwealth University, and Doctor of Medicine degree from Medical College of Virginia/VCU, where he also completed his residency. Kishor has co-authored multiple publications, book chapters, and abstracts. In 2011, he received the Michael R. Redmond, M.D. Outstanding Young Ophthalmologist Award from the FSO. The FSO also announced the elections of Darby Miller, M.D. as president-elect, Kara Cavuoto, M.D. as secretary/treasurer, Joseph Nezgoda, M.D., M.B.A. as vice president of advocacy, David Eichenbaum, M.D. as vice president of education and Stacy Kruger, M.D. as vice president of outreach. Miller is a cornea and cataract specialist and an assistant professor in the Department of Ophthalmology at the Mayo Clinic in Jacksonville. He completed his cornea fellowship at the New York Eye and Ear Infirmary and his ophthalmology residency and medical school at George Washington University Medical Center. Miller completed his internship and earned his M.S. degree at Georgetown University. He completed his M.P.H. degree at Harvard University and his undergraduate studies at the University of Kansas. In 2016, Miller received the Michael R. Redmond, M.D. Outstanding Young Ophthalmologist Leadership Award. Cavuoto is an assistant professor of clinical ophthalmology and clinical pediatrics at Bascom Palmer Eye Institute at the University of Miami Miller School of Medicine. She evaluates and treats patients with pediatric eye disorders, including amblyopia and strabismus, as well as adults with strabismus. In addition, Cavuoto serves as the director of medical student education in ophthalmology at the University of Miami. In this role, she oversees all ophthalmology clerkships and pre-clinical graduate coursework and advises University of Miami medical students applying for ophthalmology residency. Cavuoto attended both college and medical school at the University of Miami as part of the Honors Program in Medicine combined BS-MD degree program. She completed an internship in internal medicine at Jackson Memorial Hospital followed by ophthalmology residency and a pediatric ophthalmology and strabismus fellowship at Bascom Palmer Eye Institute. Nezgoda is a fellowship trained retina specialist at the Florida Eye Microsurgical Institute, Inc., in West Palm Beach. His area of focus is on the treatment of macular degeneration, diabetic retinopathy, retinal detachment, inflammatory eye disease and other diseases of the retina and vitreous. Nezgoda completed a fellowship in medical and surgical diseases at the University of California and has also been a researcher at the National Institutes of Health. An honors graduate of Georgetown University, Nezgoda attended medical school at UMDNJ-Robert Wood Johnson Medical School. While there, he received several scholarships including the Gold Humanism Honor Society. Nezgoda also received the Excellence in Teaching Award from UMDNJ-RWJMS "in honor of dedicated service to clinical skills education in the preclinical years" for being the first coordinator of the Student Teaching Elective. Nezgoda performed post-graduate training at the Albert Einstein Medical Center, the New York Eye and Ear Infirmary, and Case Western University/University Hospitals of Cleveland. Eichenbaum, who was re-elected to the same role, has been employed at Retina Vitreous Associates of Florida -- St. Petersburg, Clearwater, and Tampa -- since 2007. He is also a clinical assistant professor in the Department of Ophthalmology at the University of South Florida College of Medicine. Eichenbaum received his Bachelor of Arts and medical degrees from the University of South Florida. He completed a fellowship in vitreoretinal surgery at Tufts/Ophthalmic Consultants of Boston and has co-authored multiple research interests and articles. He is a Fellow of the American Academy of Ophthalmology. In 2015, Eichenbaum received the Michael R. Redmond, M.D. Outstanding Young Ophthalmologist Award from the FSO. Kruger, who was also re-elected to the same role, is an attending physician at Stacey J. Kruger, M.D. & Associates, P.A. in Miami, Fla. Kruger received a Bachelor of Arts degree from Washington University in St. Louis and her medical degree from S.U.N.Y. Health Science Center at Brooklyn. She completed a residency in ophthalmology at Mt. Sinai School of Medicine in New York and completed a pediatric ophthalmology fellowship at the Medical University of South Carolina. In her private practice in Miami, she offers a full range of ophthalmic and contact lens services for children and young adults, as well as adult strabismus. Kruger has also been an active board member for the For Eye Care Foundation, the charitable arm of the FSO. She was the leader of an Amblyopia Awareness Campaign in 2015 and has organized and participated at numerous vision screening events around the state. In 2016, Kruger received the James W. Clower, Jr. M.D., Community Service Award for her contributions. ABOUT THE FLORIDA SOCIETY OF OPHTHALMOLOGY The Florida Society of Ophthalmology (FSO) has a rich history of serving patients since its founding in 1939 as the Florida Society of Ophthalmology and Otolaryngology. Today, the organization represents more than 500 physician members throughout the state and is focused on advancing patient care and protecting the medical specialty of ophthalmology. For more information, please visit the FSO website at www.mdeye.org. Image Available: http://www.marketwire.com/library/MwGo/2017/5/25/11G139704/Images/Krishna_Kishor-cda38e3fcb78b364928f2fc86396ffcf.jpg Image Available: http://www.marketwire.com/library/MwGo/2017/5/25/11G139704/Images/Darby_Miller-9a4549f70f9c9d7ba2e418dffb6098b1.jpg Image Available: http://www.marketwire.com/library/MwGo/2017/5/25/11G139704/Images/Kara_Cavuoto-20493c59afbea7fd81371a71d56d0ea7.jpg Image Available: http://www.marketwire.com/library/MwGo/2017/5/25/11G139704/Images/Joseph_Nezgoda-1732d643a43aa43a92e189d9e6db2b32.jpg Image Available: http://www.marketwire.com/library/MwGo/2017/5/25/11G139704/Images/David_Eichenbaum-634edc2c50ea9093910099d4e593370a.jpg Image Available: http://www.marketwire.com/library/MwGo/2017/5/25/11G139704/Images/Stacey_Kruger-ba69bf4444f791369d783f863079b5a5.jpg
News Article | June 20, 2017
The International Association of HealthCare Professionals is pleased to welcome Dr. Elissa Jeanne Santoro, MD, to their prestigious organization with her upcoming publication in The Leading Physicians of the World. She is a highly-trained Breast Surgical Oncologist with expertise in all facets of her work. Dr. Elissa Jeanne Santoro has been practicing for over 47 years and is currently on staff at the Center for Breast Health and Disease Management, a part of St. Barnabas Medical Center in Livingston, New Jersey. Dr. Elissa Jeanne Santoro obtained her Doctor of Medicine Degree from the Women’s Medical College of Pennsylvania in 1965, where she also completed a straight surgical internship. After two years of Surgical residency at Woman’s Medical, she completed her Surgical residency at St. Vincent’s Hospital in New York City, and became the first woman to be Chief Surgical Resident. There, she received an ACS postdoctoral Fellowship in cancer training. At New York Medical College she was awarded a postdoctoral Fellowship from The National Cancer Institute, and was also on the surgical faculty. Dr. Santoro then moved to New Jersey and joined the faculty at UMDNJ. Later, she joined St. Barnabas Medical Center in Livingston, NJ private practice and in 1977 opened the first Breast Oncology practice in New Jersey. Dr. Santoro is certified by the American Board of Surgery in General Surgery, and is particularly renowned as an expert in breast surgery and surgical oncology. She remains a professional member of many professional organizations, including the American Society of Clinical Oncology, the American Society of Breast Surgeons, the American Society of Breast Disease, the Medical Society of New Jersey, and is the First Woman President of the New Jersey American Cancer Society. She attributes her success to her upbringing and her determination to become a doctor at a young age. When not assisting patients, Dr. Santoro enjoys traveling, reading, and hot air ballooning. Learn more about Dr. Santoro here: http://www.barnabashealth.org/Center-for-Breast-Health-and-Disease-Management.aspx and by reading her upcoming publication in The Leading Physicians of the World. FindaTopDoc.com is a hub for all things medicine, featuring detailed descriptions of medical professionals across all areas of expertise, and information on thousands of healthcare topics. Each month, millions of patients use FindaTopDoc to find a doctor nearby and instantly book an appointment online or create a review. FindaTopDoc.com features each doctor’s full professional biography highlighting their achievements, experience, patient reviews and areas of expertise. A leading provider of valuable health information that helps empower patient and doctor alike, FindaTopDoc enables readers to live a happier and healthier life. For more information about FindaTopDoc, visit: http://www.findatopdoc.com
News Article | June 6, 2017
Less than one year ago, Dr. Abend founded the Sañare Center for Integrative Medicine. According to its website, it "offers a unique blend of Eastern and Western principles and practices in a welcoming, peaceful and personalized environment." With over 25 years of experience in his role, Dr. Abend’s focus is on nonsurgical spinal treatments, sports injuries and neuropathy. He is double board certified in Family Medicine and Physical Medicine and Rehabilitation. Additionally, Dr. Abend has served as the Founder, Medical Director, and President of Consultants in Rehabilitation and Pain Medicine for the past 27 years. He is also the President and Founder of the Union County Surgical Center, and the Founder and Past President, of the Robert Wood Johnson University Ambulatory Surgical Center. Dr. Abend has also served as Past Chief Medical Officer of Partners Healthcare, an Institutional Pharmacy and Hospice that offers Infusion, Home and Durable Healthcare Equipment. He is also the Past Medical Director and Founder of Comprehensive Rehabilitation Institute of New Jersey, a unique and sophisticated underwater gymnasium and a full land rehabilitation center sold to a Major Medical University Center. Furthermore, Dr. Abend is the Founder and Preceptor for the Department of Family Medicine Residency Program at Robert Wood Johnson Medical School in Desensitizing and Teaching Residents, and working with Children and Adults with Autism and the Medical Complexities (Gastrointestinal, Seizures, and Psychiatric issues). Currently he is in the process of founding a Vocational Program (Farming) for Special Needs Adults so they can contribute to society and have a purposeful and meaningful life. In recognition of his work, he has been the Founding Preceptor since the inception of the Kessler Institute Musculoskeletal Pain Management Fellowship Program for the past ten years. He is also the Past President of both the New Jersey Society of Physical Medicine and Rehabilitation and the New Jersey Society of Medical Specialties. Dr. Abend has been educated at many prominent institutions: Drew University, UMDNJ, and Rowan University School of Osteopathic Medicine. He was a Resident, and Chief Resident in the Departments of Physical Medicine and Rehabilitation and Pain Medicine, and in Family Medicine at Rutgers-Robert Wood Johnson Hospital. Additionally, he completed a Sports Medicine Fellowship in the Department of Family Medicine at Rutgers-Robert Wood Johnson Medical School. Just this year, he was listed in the Leading Physicians of the World, 2016, for his work in Medicine, as well as his Extensive Humanitarian work in the field of Autism. In 2015, Dr. Abend was awarded the Dr. Margaret L. Bauman Award, which is awarded to Medical Professionals who goes above and beyond the call of duty in their field. In this case, Dr. Abend received the award due to his contributions towards Autism. This was also the expertise of the award's founder, Dr. Margaret L. Bauman, who had a 45-year accomplished career in the Autism field. Some of Dr. Abend’s many accomplishments include: Also due to his work in the field of Autism, he was awarded the Jefferson Award for Medicine, a prestigious national recognition, honoring community and public volunteerism, for the State of New Jersey and Region. He was also awarded the 2011 Citizen of the Year Award from Warren Township. To further his professional development, Dr. Abend is a Diplomate with the Association of Academic Physiatrists, a Fellow with the Academy of Physical Medicine and Rehabilitation and is a member of the Physiatric Association of Spine, Sports and Occupational Medicine. Dr. Paul Abend is has 4 convenient Office locations in Bernardsville, Clark, RWJRAHWAY Hospital and North Brunswick. To view his full online profile and see his other locations, please follow this link: http://www.njtopdocs.com/DrAbend About Us NJ Top Docs is a comprehensive information resource of Top Doctors, Dentists and Hospitals. We are profiling over 900 Healthcare Providers and have made it convenient for you to find them. NJ Top Docs allows patients to “meet” these providers online before making their appointment. You can also follow us on Facebook – Twitter – YouTube
News Article | November 18, 2016
Marvell Scott, M.D., Discusses Treatment of Professional Athletes Using Injections That Do Not Have the Risks Associated with Steroids, Opioids, or NSAIDs. Marvell Scott, M.D., conducted a webinar about alternative pain relief treatments on October 12, 2016, which was watched by doctors from coast to coast. The event is now available to watch online HERE In the webinar, Dr. Scott discusses how he treats several musculoskeletal conditions including orthopedic surgery recovery, tennis elbow, tendonitis, tendinopathy, partial tears, post-surgical and post-traumatic arthrofibrosis, sports injuries, musculoskeletal pain, and osteoarthritis. Dr. Scott’s practice includes a wide range of patients, from some of the greatest athletes in the world to older patients dealing with high levels of disability due to intractable pain. Dr. Scott began his practice exclusively using a wide range of conventional drugs like glucocorticoid injections, but has since broadened his range of medications to include the use of natural medications, where they have proven to be effective. Today MediNatura™ injections and topical medicines are a mainstay of the alternative side of Dr. Scott’s practice. “In my practice, we have seen that the risks with Traumeel®, Zeel®, and other MediNatura™ injections are minimal in comparison with traditional glucocorticoid injections, but the benefits for pain relief are comparable,” said Dr. Scott. Many of his patients have endured exhaustive attempts to alleviate their pain through conventional treatment options, including multiple cortisone injections. “Cortisone is your synthetic version of cortisol, which is your aging hormone, so there are a lot of limitations with frequency and dosage,” said Dr. Scott. “With MediNatura™ products like Traumeel®, Zeel®, Neuralgo-Rheum®, and other injections I am able to inject a much broader spectrum of areas without weakening the tendon or suppressing the immune system.” “I treat well over 100 patients a week. Twenty to thirty injections a day, sometimes seven days a week. This may be tens of thousands of injections, and I haven’t had any real adverse reactions,” said Dr. Scott. In the webinar, Dr. Scott mentions that his professional athlete clients needed reassurance that Traumeel® and Zeel® contain no performance-enhancing drugs (PEDs). To address this concern, Dr. Scott independently hired a prestigious U.S. laboratory to conduct testing, which confirmed that the treatments are free of banned substances, including PEDs. Additionally, Traumeel® and Zeel® have never caused an issue with the random drug screening tests conducted on professional athletes. Dr. Scott completed his internal medicine residency at Mount Sinai School of Medicine’s sister hospital Cabrini Medical Center. He did his sports medicine specialty fellowship at UMDNJ-Robert Wood Johnson Medical School, where he worked with Rutgers and Princeton’s 30 varsity sports teams. Almost eight years ago, while working in northern Italy with the EuroLeague (a professional basketball league) and with the international soccer team A.C. Milan, he was introduced to the MediNatura™ products. He also learned that the doctors who treat the German Olympic team, German national soccer team, and multiple professional soccer teams such as Real Madrid and Bayern Munich, were successfully using Traumeel®. MediNatura™ Inc., a Delaware Corporation headquartered in greater Philadelphia, specializes in prescription and over the counter pharmaceuticals made from natural medicines. You can reach MediNatura™ toll-free at 1-844-633-4628 Monday through Friday from 8 a.m. to 5 p.m. MST or visit MediNatura.com MediNatura™ imports Traumeel®, Zeel®, and other injections from Germany, where they are manufactured in FDA-audited factories according to strict U.S. pharmaceutical standards for purity and sterility. Full prescribing information for Traumeel® is available at CLICK HERE and for Zeel® at CLICK HERE.
Matise M.P.,UMDNJ |
Current Topics in Developmental Biology | Year: 2011
Sonic Hedgehog (Shh) is one of three mammalian orthologs of the Hedgehog (Hh) family of secreted proteins first identified for their role in patterning the Drosophila embryo. In this review, we will highlight some of the outstanding questions regarding how Shh signaling controls embryonic development. We will mainly consider its role in the developing mammalian central nervous system (CNS) where the pathway plays a critical role in orchestrating the specification of distinct cell fates within ventral regions, a process of exquisite complexity that is necessary for the proper wiring and hence function of the mature system. Embryonic development is a process that plays out in both the spatial and the temporal dimensions, and it is becoming increasingly clear that our understanding of Shh signaling in the CNS is grounded in an appreciation for the dynamic nature of this process. In addition, any consideration of Hh signaling must by necessity include a consideration of data from many different model organisms and systems. In many cases, the extent to which insights gained from these studies are applicable to the CNS remains to be determined, yet they provide a strong framework in which to explore its role in CNS development. We will also discuss how Shh controls cell fate diversification through the regulation of patterned target gene expression in the spinal cord, a region where our understanding of the morphogenetic action of graded Shh signaling is perhaps the furthest advanced. © 2011 Elsevier Inc.
Balashov K.E.,UMDNJ |
Lindzen E.,State University of New York at Buffalo
Multiple Sclerosis Journal | Year: 2012
Background and objectives: It is widely accepted that typical acute demyelinating lesions in relapsingremitting multiple sclerosis (RRMS) exhibit vasogenic edema with increased diffusion, as demonstrated by an increased apparent diffusion coefficient on MRI. In contrast, acute ischemic lesions demonstrate cytotoxic edema with restricted diffusion. Recent reports have documented selected cases of acute demyelinating lesions exhibiting restricted diffusion (ADLRD) in MS. We aimed to assess the morphologies, distributions, signal characteristics and changes over time of nine ADLRD. An additional goal was to obtain clinical correlations and relate our findings to all previously published case reports describing ADLRD. Methods: A retrospective case series study was performed at two academic centers. MRI characteristics of nine ADLRD found in six RRMS patients were compared with typical active symptomatic contrast-enhancing lesions with increased or normal diffusion in control RRMS patients. Results: The average size of ADLRD was not significantly different from typical lesions. A periventricular location and faint signal on T2-weighted images were significantly more common for ADLRD compared with typical lesions. Two patients with ADLRD on initial MRI exhibited new ADLRD on their follow up scans. Conclusion: Our results and review of prior published cases suggest that ADLRD represent a new variant of MS lesion. The restricted diffusion that is a characteristic of ADLRD on MRI is a new challenge in the differential diagnosis of stroke in young adults. The pathogenesis of ADLRD remains to be understood. © The Author(s) 2012.
Annals of the New York Academy of Sciences | Year: 2010
Age-associated decrease in nitric oxide (NO) production may be related to an increase in cardiovascular events, sexual dysfunction, and osteoporosis. Relative NO deficiency is a plausible biological basis for NO replacement therapy. Hormone replacement therapy (HRT) enhances local NO production and rectifies NO deficiency in postmenopausal women. However, excess local production of NO aggravates bone destruction in inflammatory arthropathies. In addition to its use in alleviating angina and erectile dysfunction, NO compounds could be a valuable supplemental therapy for chronic conditions including osteoporosis. Estrogen mediates its beneficial effects in bone, in part via the NO/cGMP pathway; hence NO donor therapy is an alternative to estrogen, estrogen agonists-antagonists, and androgen receptor modulator therapy in the prevention and treatment of osteoporosis. Large numbers of animal studies and human pilot studies support the concept of using NO donors for preventing bone loss. Administration of exogenous NO or prolonging endogenous NO activity are practical ways to supplement NO. © 2010 New York Academy of Sciences.
Journal of Clinical Gastroenterology | Year: 2012
Sjogren syndrome (SS) is an autoimmune disease that affects exocrine glands and therefore may affect the gastrointestinal system, from the mouth, esophagus, and bowel to the liver and pancreas. Oral involvement in SS is mainly characterized by dryness, with a wide spectrum of symptoms, from mild-to-severe xerostomia with dysgeusia and tooth decay. The dysphagia, although common, does not correlate with the reduced salivary flow rate or the dysmotility that may be present. Dyspepsia, found in up to 23% of patients, may be associated with gastritis, reduced acid production, and antiparietal cell antibodies, but rarely pernicious anemia. Pancreatic involvement, although rare, includes pancreatitis and pancreatic insufficiency. The most common causes of liver disease are primary biliary cirrhosis, autoimmune hepatitis, nonalcoholic fatty liver disease, and hepatitis C virus (HCV). Although abnormal liver tests are found in up to 49% of patients, they are usually mild. Although sicca syndrome, abnormal histology of the salivary glands, and abnormal sialograms are common in primary biliary cirrhosis, the antibodies to Ro/SSA or La/SSB antigens are infrequent. Xerostomia, sialadenitis, abnormal salivary flow rates, and abnormal Schirmer test in HCV vary widely among the studies, although the antibodies to Ro/SSA or La/SSB are only 1%. Several studies show that HCV is in saliva, although how this may impact sicca syndrome or SS in HCV is unclear. SS as a disease of exocrine glands affects many parts of the gastrointestinal system. Copyright © 2012 by Lippincott Williams & Wilkins.